Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Tg Therapeutics (TGTX) Other Non Operating Income (2016 - 2025)

Tg Therapeutics has reported Other Non Operating Income over the past 5 years, most recently at $1.1 million for Q4 2025.

  • Quarterly results put Other Non Operating Income at $1.1 million for Q4 2025, down 55.87% from a year ago — trailing twelve months through Dec 2025 was $10.8 million (up 37.96% YoY), and the annual figure for FY2025 was $10.8 million, up 40.3%.
  • Other Non Operating Income for Q4 2025 was $1.1 million at Tg Therapeutics, down from $3.3 million in the prior quarter.
  • Over the last five years, Other Non Operating Income for TGTX hit a ceiling of $3.6 million in Q1 2025 and a floor of $604000.0 in Q1 2023.
  • Median Other Non Operating Income over the past 4 years was $1.8 million (2022), compared with a mean of $1.9 million.
  • Peak annual rise in Other Non Operating Income hit 309.43% in 2025, while the deepest fall reached 55.87% in 2025.
  • Tg Therapeutics' Other Non Operating Income stood at $1.9 million in 2022, then crashed by 53.89% to $890000.0 in 2023, then skyrocketed by 188.2% to $2.6 million in 2024, then plummeted by 55.87% to $1.1 million in 2025.
  • The last three reported values for Other Non Operating Income were $1.1 million (Q4 2025), $3.3 million (Q3 2025), and $2.8 million (Q2 2025) per Business Quant data.